/CRNX
CRNX Stock - Crinetics Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$48.01+6.36%
+$2.87 (+6.36%) • Dec 19
89
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+113.1%upside
Target: $102.31
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CRNX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$47.53 – $48.49
TARGET (TP)$102.33
STOP LOSS$44.17
RISK/REWARD1:14.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.20
52W High$54.78
52W Low$24.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.04M | $4.01M | $4.74M | $1.08M | $71,000 |
| Gross Profit | $-1,746,000 | $4.01M | $4.74M | $1.08M | $-56,927,000 |
| Gross Margin | -168.0% | 100.0% | 100.0% | 100.0% | -80178.9% |
| Operating Income | $-338,854,000 | $-222,608,000 | $-167,882,000 | $-107,702,000 | $-74,953,000 |
| Net Income | $-298,408,000 | $-214,529,000 | $-163,918,000 | $-107,641,000 | $-73,812,000 |
| Net Margin | -28720.7% | -5345.9% | -3460.4% | -9985.3% | -103960.6% |
| EPS | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 |
Company Overview
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
75%
Hold / Neutral
2
25%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish2 Neutral/Bearish
Price Targets
$48
Average Target
↑ 0.9% Upside
Now
$35
Low
$48
Average
$68
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 10th 2025 | Goldman | Initiation | Neutral | $36 |
| March 25th 2025 | Stifel | Initiation | Buy | $60 |
| February 11th 2025 | TD Cowen | Initiation | Buy | - |
| February 4th 2025 | Wolfe Research | Initiation | Peer Perform | - |
| January 22nd 2025 | Jefferies | Upgrade | Buy | $55 |
| March 6th 2024 | Citigroup | Initiation | Buy | $68 |
| January 16th 2024 | Morgan Stanley | Initiation | Overweight | $50 |
| December 21st 2023 | Jefferies | Initiation | Hold | $35 |
| November 20th 2023 | JP Morgan | Resumed | Overweight | $35 |
| October 24th 2023 | Cantor Fitzgerald | Resumed | Overweight | $50← $52 |
| August 31st 2023 | Oppenheimer | Initiation | Outperform | $40 |
| April 24th 2023 | Piper Sandler | Initiation | Overweight | $56 |
| March 30th 2023 | Robert W. Baird | Initiation | Outperform | $48 |
Earnings History & Surprises
CRNXBeat Rate
6%
Last 18 quarters
Avg Surprise
-9.8%
EPS vs Estimate
Beats / Misses
1/16
1 met exactly
Latest EPS
$-1.38
Q4 2025
EPS Surprise History
Q1 24
-1.1%
$-0.90vs$-0.89
Q2 24
-10.7%
$-0.93vs$-0.84
Q3 24
-9.3%
$-0.94vs$-0.86
Q4 24
-5.4%
$-0.96vs$-0.91
Q1 25
+4.3%
$-0.88vs$-0.92
Q2 25
-5.1%
$-1.04vs$-0.99
Q3 25
-8.8%
$-1.23vs$-1.13
Q4 25
-8.7%
$-1.38vs$-1.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-1.35 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.27 | $-1.38 | -8.7% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-1.13 | $-1.23 | -8.8% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.99 | $-1.04 | -5.1% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.92 | $-0.88 | +4.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.91 | $-0.96 | -5.4% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.86 | $-0.94 | -9.3% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.84 | $-0.93 | -10.7% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.89 | $-0.90 | -1.1% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.89 | $-1.01 | -13.5% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.85 | $-0.94 | -10.6% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.82 | $-0.85 | -3.7% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-0.82 | $-0.84 | -2.4% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.78 | $-0.78 | 0.0% | = MET |
Q3 2022 | Aug 12, 2022 | $-0.62 | $-0.81 | -30.6% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.56 | $-0.73 | -30.4% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | $-0.57 | $-0.68 | -19.3% | ✗ MISS |
Q4 2021 | Nov 5, 2021 | $-0.70 | $-0.73 | -4.3% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.60 | $-0.70 | -16.7% | ✗ MISS |
Latest News
Crinetics Pharma Announces First Patient Dosed In CALM-CAH Phase 3 Trial Evaluating Investigational Candidate Atumelnant For Proposed Treatment Of Classic Congenital Adrenal Hyperplasia
📈 PositiveBenzinga•Dec 11, 2025, 09:11 PM
Crinetics Pharmaceuticals shares are trading higher after the company announced it does its first patient n the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2-positive neuroendocrine tumors and other SST2-expressing solid tumors.
📈 PositiveBenzinga•Dec 3, 2025, 05:03 PM
Crinetics Announces First Patient Dosed In Phase 1/2 Study Evaluating CRN09682 In Patients With Advanced SST2-Positive Neuroendocrine Tumors And Other SST2-Expressing Solid Tumors
📈 PositiveBenzinga•Dec 3, 2025, 01:07 PM
Crinetics Randomizes First Patient In Phase 3 CAREFNDR Trial Of Oral Paltusotine For Carcinoid Syndrome
➖ NeutralBenzinga•Nov 20, 2025, 09:11 PM
Citizens Maintains Market Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $108
➖ NeutralBenzinga•Nov 7, 2025, 01:43 PM
Crinetics Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 7, 2025, 01:41 PM
CRNX stock has given up its prior loss. Crinetics Pharmaceuticals shares were trading lower after the company reported worse-than-expected Q3 financial results.
➖ NeutralBenzinga•Nov 6, 2025, 10:09 PM
Crinetics Pharmaceuticals Reports Cash Balance Of $1.1B, Reiterates Cash Burn Of $340-370M And Cash Runway Into 2029
📈 PositiveBenzinga•Nov 6, 2025, 09:41 PM
Crinetics Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 6, 2025, 09:39 PM
Crinetics Pharmaceuticals Q3 EPS $(1.38) Misses $(1.25) Estimate, Sales $143.000K Miss $363.615K Estimate
📉 NegativeBenzinga•Nov 6, 2025, 09:07 PM
Crinetics To Present At North American Neuroendocrine Tumor Society Annual Meeting Oct. 23-25
➖ NeutralBenzinga•Oct 23, 2025, 12:15 PM
Oppenheimer Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $87
📈 PositiveBenzinga•Sep 30, 2025, 01:46 PM
Morgan Stanley Maintains Overweight on Crinetics Pharmaceuticals, Raises Price Target to $77
📈 PositiveBenzinga•Sep 29, 2025, 05:05 PM
Goldman Sachs Maintains Neutral on Crinetics Pharmaceuticals, Raises Price Target to $40
➖ NeutralBenzinga•Sep 26, 2025, 05:07 PM
Crinetics Pharmaceuticals shares are trading higher after the FDA approved PALSONIFY. Also, Baird and JMP Securities raised their respective price targets on the stock.
📈 PositiveBenzinga•Sep 26, 2025, 01:07 PM
JMP Securities Maintains Market Outperform on Crinetics Pharmaceuticals, Raises Price Target to $143
📈 PositiveBenzinga•Sep 26, 2025, 12:11 PM
Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Sep 26, 2025, 11:00 AM
Baird Maintains Outperform on Crinetics Pharmaceuticals, Raises Price Target to $62
📈 PositiveBenzinga•Sep 26, 2025, 10:28 AM
Crinetics Pharmaceuticals Receives FDA Approval For PALSONIFY; PALSONIFY Is Expected To Be Available In The U.S. In Early October
📈 PositiveBenzinga•Sep 25, 2025, 09:33 PM
Trading Halt: Halted at 5:18:40 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 25, 2025, 09:18 PM
Frequently Asked Questions about CRNX
What is CRNX's current stock price?
Crinetics Pharmaceuticals, Inc. (CRNX) is currently trading at $48.01 per share. The stock has moved +6.36% today.
What is the analyst price target for CRNX?
The average analyst price target for CRNX is $102.33, based on 1 analyst.
What sector is Crinetics Pharmaceuticals, Inc. in?
Crinetics Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CRNX's market cap?
Crinetics Pharmaceuticals, Inc. has a market capitalization of $4.56 billion, making it a mid-cap company.
Does CRNX pay dividends?
No, Crinetics Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACAD
ACADIA Pharmaceuticals Inc.
$27.16
Mkt Cap: $4.6B
AKRO
Akero Therapeutics, Inc.
$54.65
Mkt Cap: $4.5B
DYN
Dyne Therapeutics, Inc.
$19.85
Mkt Cap: $2.8B
IMVT
Immunovant, Inc.
$26.68
Mkt Cap: $4.7B
KYMR
Kymera Therapeutics, Inc.
$83.99
Mkt Cap: $6.0B
NAMS
NewAmsterdam Pharma Company N.V.
$35.11
Mkt Cap: $4.0B
PRAX
Praxis Precision Medicines, Inc.
$272.92
Mkt Cap: $5.8B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
VKTX
Viking Therapeutics, Inc.
$35.19
Mkt Cap: $4.0B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
Explore stocks similar to CRNX for comparison